ArticleFrontiers in cell and developmental biology2026
Single-cell transcriptomic characterization of the immunosuppressive tumor immune microenvironment in hepatocellular carcinoma: implications for SBRT-based radio-immunotherapy.
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) carries dismal prognosis, and the tumor immune microenvironment (TIME) critically determines the efficacy of SBRT-based radio-immunotherapy; yet its single-cell architecture remains undefined. Methods: We analyzed scRNA-seq data (GEO: GSE149614; single patient HCC07, stage IIIB; normal liver, primary tumor, PVTT) using a standardized pipeline including dimensionality reduction, clustering, immune signature scoring, and checkpoint profiling (FDR <0.05). Results: scRNA-seq identified six major cell types across 25 clusters: myeloid cells expanded from 22.4% (normal) to 46.5% (tumor), while T/NK cells declined from 66.5% to 20.0%. SPP1, CXCL8, APOE, TGF-β1, IL-10, and VEGFA were upregulated in tumor/PVTT, with multi-checkpoint T cell exhaustion (PDCD1, LAG3, TIGIT, CTLA4) dominating tumor-infiltrating lymphocytes. RT-qPCR/ELISA confirmed M2-conditioned medium upregulated SPP1 (∼3.4-fold) and CXCL8 (∼4.1-fold; p < 0.001) in Hepatocellular carcinoma cells, and attenuated radiation-induced calreticulin exposure by ∼40% (p < 0.05). Conclusion: The HCC TIME is profoundly immunosuppressive, driven by myeloid dominance and multi-checkpoint T cell exhaustion. The immunosuppressive microenvironment attenuates SBRT-induced ICD, providing direct mechanistic rationale for combining macrophage reprogramming, dual checkpoint blockade, and anti-angiogenic strategies with SBRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.